Leading publicly traded gene-editing and CRISPR-focused equities frequently highlighted by institutional analysts include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM). These pioneers offer exposure to revolutionary genomic medicines, though they carry elevated clinical trial and volatility risks. What is your risk profile and long-term portfolio strategy?